PMID- 19935716
OWN - NLM
STAT- MEDLINE
DCOM- 20100312
LR  - 20211203
IS  - 1476-5594 (Electronic)
IS  - 0950-9232 (Print)
IS  - 0950-9232 (Linking)
VI  - 29
IP  - 7
DP  - 2010 Feb 18
TI  - Embryoid body formation of human amniotic fluid stem cells depends on mTOR.
PG  - 966-77
LID - 10.1038/onc.2009.405 [doi]
AB  - Human amniotic fluid stem cells (hAFSCs) harbor high proliferative capacity and 
      high differentiation potential and do not raise the ethical concerns associated 
      with human embryonic stem cells. The formation of three-dimensional aggregates 
      known as embryoid bodies (EBs) is the principal step in the differentiation of 
      pluripotent embryonic stem cells. Using c-Kit-positive hAFSC lines, we show here 
      that these stem cells harbor the potential to form EBs. As part of the two kinase 
      complexes, mTORC1 and mTORC2, mammalian target of rapamycin (mTOR) is the key 
      component of an important signaling pathway, which is involved in the regulation 
      of cell proliferation, growth, tumor development and differentiation. Blocking 
      intracellular mTOR activity through the inhibitor rapamycin or through specific 
      small interfering RNA approaches revealed hAFSC EB formation to depend on mTORC1 
      and mTORC2. These findings demonstrate hAFSCs to be a new and powerful biological 
      system to recapitulate the three-dimensional and tissue level contexts of in vivo 
      development and identify the mTOR pathway to be essential for this process.
FAU - Valli, A
AU  - Valli A
AD  - Department of Medical Genetics, Medical University of Vienna, Vienna, Austria.
FAU - Rosner, M
AU  - Rosner M
FAU - Fuchs, C
AU  - Fuchs C
FAU - Siegel, N
AU  - Siegel N
FAU - Bishop, C E
AU  - Bishop CE
FAU - Dolznig, H
AU  - Dolznig H
FAU - Madel, U
AU  - Madel U
FAU - Feichtinger, W
AU  - Feichtinger W
FAU - Atala, A
AU  - Atala A
FAU - Hengstschlager, M
AU  - Hengstschlager M
LA  - eng
GR  - R01 HD060097/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091123
PL  - England
TA  - Oncogene
JT  - Oncogene
JID - 8711562
RN  - 0 (CRTC2 protein, human)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Multiprotein Complexes)
RN  - 0 (Proteins)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Amniotic Fluid/*cytology
MH  - Animals
MH  - Cell Aggregation
MH  - Cell Line
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/*metabolism
MH  - Mechanistic Target of Rapamycin Complex 1
MH  - Multiprotein Complexes
MH  - Protein Serine-Threonine Kinases/*metabolism
MH  - Proteins
MH  - Stem Cells/*cytology/*metabolism
MH  - TOR Serine-Threonine Kinases
MH  - Transcription Factors/metabolism
PMC - PMC8330845
MID - NIHMS511193
COIS- Conflict of interest The authors declare no conflict of interest.
EDAT- 2009/11/26 06:00
MHDA- 2010/03/13 06:00
PMCR- 2021/08/03
CRDT- 2009/11/26 06:00
PHST- 2009/11/26 06:00 [entrez]
PHST- 2009/11/26 06:00 [pubmed]
PHST- 2010/03/13 06:00 [medline]
PHST- 2021/08/03 00:00 [pmc-release]
AID - onc2009405 [pii]
AID - 10.1038/onc.2009.405 [doi]
PST - ppublish
SO  - Oncogene. 2010 Feb 18;29(7):966-77. doi: 10.1038/onc.2009.405. Epub 2009 Nov 23.